These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 31331295

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience.
    Striefler JK, Brandes F, Baur A, Pfitzner BM, Kaul D, Rau D, Dörr A, Schmiester M, Koulaxouzidis G, Bullinger L, Märdian S, Flörcken A.
    BMC Cancer; 2020 Jan 29; 20(1):68. PubMed ID: 31996176
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
    Higuchi T, Miyake K, Sugisawa N, Oshiro H, Zhang Z, Razmjooei S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM.
    Cancer Lett; 2019 Jun 01; 451():122-127. PubMed ID: 30867142
    [Abstract] [Full Text] [Related]

  • 5. Olaratumab for advanced soft tissue sarcoma.
    Tobias A, O'brien MP, Agulnik M.
    Expert Rev Clin Pharmacol; 2017 Jul 01; 10(7):699-705. PubMed ID: 28447475
    [Abstract] [Full Text] [Related]

  • 6. Olaratumab in soft tissue sarcoma - Current status and future perspectives.
    Antoniou G, Lee ATJ, Huang PH, Jones RL.
    Eur J Cancer; 2018 Mar 01; 92():33-39. PubMed ID: 29413687
    [Abstract] [Full Text] [Related]

  • 7. Olaratumab for the treatment of advanced soft tissue sarcoma.
    Okuno SH, Maran A, Robinson SI.
    Expert Rev Anticancer Ther; 2017 Oct 01; 17(10):883-887. PubMed ID: 28862476
    [Abstract] [Full Text] [Related]

  • 8. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
    Andrick BJ, Gandhi A.
    Ann Pharmacother; 2017 Dec 01; 51(12):1090-1098. PubMed ID: 28778132
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Olaratumab for soft tissue sarcoma.
    Teyssonneau D, Italiano A.
    Expert Opin Biol Ther; 2017 Aug 01; 17(8):1019-1025. PubMed ID: 28691538
    [Abstract] [Full Text] [Related]

  • 13. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE.
    Cancer Res; 2002 Apr 01; 62(7):2034-42. PubMed ID: 11929822
    [Abstract] [Full Text] [Related]

  • 14. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
    Mo G, Baldwin JR, Luffer-Atlas D, Ilaria RL, Conti I, Heathman M, Cronier DM.
    Clin Pharmacokinet; 2018 Mar 01; 57(3):355-365. PubMed ID: 28620891
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma.
    Martín-Broto J, Pousa AL, Brohl AS, Van Tine BA, Powers B, Stacchiotti S, Blay JY, Hu JS, Oakley GJ, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL.
    Mol Cancer Ther; 2021 Jan 01; 20(1):132-141. PubMed ID: 33177152
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma.
    Van Renterghem B, Wozniak A, Castro PG, Franken P, Pencheva N, Sciot R, Schöffski P.
    Int J Mol Sci; 2022 Jul 06; 23(14):. PubMed ID: 35886842
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.